ASCO 2020丨陈洁教授:纵使微小,也需努力前行,ASCO上NETs相关研究

2020-06-20 ioncology 肿瘤瞭望

陈洁教授:

陈洁教授:今年ASCO上,关于NETs有数篇摘要值得关注,包括一篇流行病学摘要,两篇分子标记物摘要,两篇PRRT治疗的摘要,以及三篇化疗和分子靶向治疗的摘要。

流行病学

研究简介

关于NETs患者肿瘤死亡风险的流行病学研究

Risk of cancer-specific death for patients diagnosed with neuroendocrine

tumors: A population-based analysis.(4605 Poster Session Board #213)

First Author: Julie Hallet, OdetteCancer Centre, Toronto, ON, Canada

陈洁教授:加拿大的一项流行病学调查,比较了NETs患者中肿瘤和非肿瘤相关原因死亡的风险比。结论:在NETs患者中,肿瘤相关死亡显著高于其他原因导致的死亡,但肿瘤相关死亡风险在NETs患者中存在异质性,主要表现在肿瘤的原发病灶对肿瘤相关死亡的影响上, 肿瘤导致直接死亡患者以原发部位为肺和支气管以及胰腺为最多,反之胃、小肠和结肠的NETs患者中非肿瘤相关死亡的原因超过肿瘤相关的死亡原因。

分子标记物

研究简介

胃肠胰神经内分泌肿瘤(GEP-NENs)患者中 DLL3 表达与 RB1 缺失的相关性及预后意义。

Correlation of DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms with loss of RB1 and prognostic significance.(4611 Poster Session,Board #219)

First Author: Chiara Liverani, Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

陈洁教授:关于肿瘤标记物的一项来自意大利的基础研究,其主要是探索DLL-3在高级别NENs中的表达,研究结果表明在神经内分泌癌(NEC)中,DLL-3的表达显著高于NETs,并且DLL-3的表达与RB-1的缺失有关。DLL-3表达的患者其68Ga-PET/CT 扫描往往也呈阴性且预后不佳,因此DLL3蛋白可能像RB和TP53一样,作为一个潜在鉴别NEN分化好坏,是NET还是NEC的重要生物分子标记物。

试验简介

神经内分泌肿瘤诊断技术血清嗜铬素A(CgA)与NETest检出有效率对比研究

 

Inefficacy of chromogranin a assays as neuroendocrine tumor diagnostic tools compared to the NETest. (4612 Poster Session  Board #220)

First Author:Anna Malczewska, Medical University of Silesia, Katowice, Poland

陈洁教授:一项来自波兰的关于NETs肿瘤标记物的研究,比较传统的NETs通用标记物血清CgA和近几年开发出来的新兴液体活检的标记物NETest对NET的检出率。结果表明, CgA对于NETs的总体检出率只有21-35%,而NETest对NETs患者检出率则高达99%。因此NETest显著优于传统的血清CgA的检测,在未来有可能使用 NETest取代传统的血清CgA检测。

PRRT治疗

研究简介

接受 177Lu-奥曲肽PRRT治疗的转移性胃肠胰神经内分泌肿瘤(mGEP-NETs)患者的临床结局分析-治疗顺序和组合对死亡率的影响。

 

Outcome analyses in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with177Lu-DOTATATE – Impact of treatment order and combination on mortality.(4606 Poster Session ,Board #214)

First Author: Alexander Rheinhard Siebenhuener, Klinik fur Medizinische

Onkologie und Hamatologie, UniversitatsSpital Zurich, Z urich, Switzerland

陈洁教授:在PRRT治疗领域,一项来自瑞士的研究,回顾性分析了41例mGEP-NETs患者采用177Lu-奥曲肽的治疗耐受性以及患者生活质量情况,结论是PRRT治疗患者耐受性良好,生活质量没有明显下降。此外这个研究很有意思的一个结果是如果是在PRRT治疗之前使用过选择性体内放射治疗(SIRT)的患者,可能会导致死亡率上升,特别是pNETs患者。反之使用PRRT治疗以后,再使用长效生长抑素类似物维持治疗的患者则有生存的获益趋势。看起来PRRT联合其他治疗方式的先后使用顺序可能影响患者的总生存期,当然这项研究还只是一个回顾性研究,未来希望有前瞻性研究进一步探索。

研究简介

澳大利亚胃肠道试验组 (AGITG) CONTROL NET 研究:评价 177Lu-奥曲肽PRRT (177LuTate PRRT) 联合CAPTEM(卡培他滨+替莫唑胺)方案化疗疗效性 的II 期研究——胰腺和更新的中肠神经内分泌肿瘤 (pNETS,mNETS)初步结果。

 

Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study:

Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor

radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).(4608 Poster Session ,Board #21)

First Author: Nick Pavlakis, Northern Cancer Institute, St Leonards, Sydney, Australia

陈洁教授:这项来自澳大利亚的并列前瞻性II期临床研究对比了177LuTate-PRRT联合CAPTEM方案联合对比177LuTate-PRRT对转移性中肠神经内分泌肿瘤的疗效,以及177LuTate-PRRT和CAPTEM方案联合对比CAPTEM方案对转移性胰腺神经内分泌肿瘤的疗效。此项研究目前入组了75名患者,其中中肠神经内分泌肿瘤47例,胰腺神经内分泌肿瘤28例,初步研究数据显示,CAPTEM联合PRRT组无论是对于中肠神经内分泌肿瘤,还是对于胰腺神经内分泌肿瘤的治疗上,虽然PFS没有显示出明显差异,但ORR似乎有增加趋势,在胰腺神经内分泌瘤患者联合方案优于单用CAPTEM化疗,对于中肠神经内分泌瘤,ORR联合方案优于单用PRRT。当然联合方案也相应有更高的3到4级毒性。

药物领域研究简介

SANET-ep研究:一项比较索凡替尼与安慰剂治疗晚期胰腺外神经内分泌肿瘤的III期临床试验中关于患者耐受性和生活质量的研究

 

Health-related quality-of-life results from SANET-ep: A phase III study of

surufatinib versus placebo for advanced extrapancreatic neuroendocrine

tumors. (4613 Poster Session ,Board #221)

First Author: Chunmei Bai, Peking Union Medical College Hospital,Beijing, China

陈洁教授:靶向药物领域,值得关注的是国产新药索凡替尼。在去年ESMO大会上报道了SANET-ep试验索凡替尼对于非胰腺来源NETs患者的疗效,今年ASCO上报道的研究则针对索凡替尼在非胰腺来源NETs患者中使用的毒性、耐受性以及对患者生活质量的影响,结果表明凡替尼的临床耐受性较好,接受治疗的患者可保持相对良好的生活质量。期待这个药物在胰腺神经内分泌肿瘤的研究结果。

研究简介

G3 神经内分泌肿瘤 (NET G3) 不同化疗方案治疗结局的多中心分析。

Multicenter analysis of treatment outcomes for well differentiated grade 3

neuroendocrine tumors (NET G3).(4607 Poster Session ,Board #215)

First Author: Leonidas Apostolidis,Department of Medical Oncology, National Center for Tumor Diseases,Heidelberg University Hospital, Heidelberg, Germany

陈洁教授:化疗的临床研究,首先是来自德国的一个多中心回顾性临床研究,关于临床上治疗选择比较困难的G3 NETs患者。研究比较了不同的化疗方案一线治疗G3 NET的结果。化疗方案包括铂类为基础的联合化疗方案、FOLFOX方案,以替莫唑胺为基础的联合化疗方案以及以链脲霉素为基础的联合化疗方案,结果表明,几个方案相比较,以FOLFOX方案客观有效率最高,而替莫唑胺为基础的方案PFS最长。这一研究提示临床可以针对不同目的进行化疗方案选择,例如如果外科需要做术前转化治疗,可能选取客观有效率最高的化疗方案就比较合适。如果是晚期肿瘤,治疗目的主要是为了延长患者的PFS或者是OS,那么选择一个可以获得最长的PFS时间的方案可能就更合适。

研究简介

CAPTEM方案(卡培他滨/替莫唑胺)在 NETs 患者治疗中毒副作用分析

Toxicity analysis of capecitabine/temozolomide in NETs.(4614 Poster Session ,Board #222)

First Author: Taymeyah E. Al-Toubah, H. Lee Moffitt Cancer Center and Research In stitute, Tampa, FL

陈洁教授:最后一个关于化疗的摘要是来自于美国的关于CAPTEM方案临床长期使用的毒性和安全性的一个大样本回顾性研究。总共纳入了420例病人,结果与目前我们在临床使用的经验相似,CAPTEM方案总体安全性和耐受性较好。研究中只有极少部分病人出现4度血液学毒性,有意思的是发生4度血液学毒性的女性患者数量显著高于男性患者;此外3例患者出现骨髓增生异常综合征,均为化疗前进行过PRRT治疗者。机会性感染发生率极低。

总结

陈洁教授:综合而言,每年ASCO上,NETs都是一个不起眼的小角色,不过总有一些摘要,能够给我们临床带来一些信息和启发,也是此次我对ASCO NET摘要进行梳理后给大家分享的一些小亮点。

专家简介

陈洁  主任医师

中山大学附属第一医院消化内科副主任

欧洲神经内分泌肿瘤学会(ENETS)顾问委员会委员

欧洲神经内分泌肿瘤学会(ENETS)会员

国际神经内分泌肿瘤联盟(INCA)医疗顾问委员会委员

中国抗癌协会胰腺癌专业委员会神经内分泌肿瘤学组(CSNET)组长

中华医学会消化病学分会胃肠激素与神经内分泌肿瘤学组副组长

中国医师协会胰腺病分会胰腺神经内分泌肿瘤专委会副主任委员

中国医促会神经内分泌肿瘤分会常委

中国抗癌协会胰腺癌专业委员会常委

中国抗癌协会整合肿瘤学分会常委

中国医师协会整合医学医师分会整合肿瘤学专业委员会副主任委员

中华医学会肿瘤学分会胰腺肿瘤学组委员

广东省医师协会消化科医师分会副主任委员

广东省医学会消化病分会肿瘤学组副组长

中国临床肿瘤学会(CSCO)罕见肿瘤专家委员会委员

ENETS 官刊Neuroendocrinology 副主编(Associate editor)

Journal of Pancreatology 编委

中华消化杂志通讯编委

专注于神经内分泌肿瘤的诊治和研究

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1939090, encodeId=db4a1939090a9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 04 00:32:32 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800504, encodeId=f01f1800504b7, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Jan 26 02:32:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734228, encodeId=d0d71e342281c, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Apr 08 12:32:32 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344248, encodeId=fdb7134424876, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2830, encryptionId=7649283021, topicName=ASCO 2020)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jun 22 10:32:32 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553779, encodeId=3d0e1553e790d, content=<a href='/topic/show?id=5332126e5b5' target=_blank style='color:#2F92EE;'>#NETs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12675, encryptionId=5332126e5b5, topicName=NETs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16414422875, createdName=wincls, createdTime=Mon Jun 22 10:32:32 CST 2020, time=2020-06-22, status=1, ipAttribution=)]
    2021-01-04 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1939090, encodeId=db4a1939090a9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 04 00:32:32 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800504, encodeId=f01f1800504b7, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Jan 26 02:32:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734228, encodeId=d0d71e342281c, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Apr 08 12:32:32 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344248, encodeId=fdb7134424876, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2830, encryptionId=7649283021, topicName=ASCO 2020)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jun 22 10:32:32 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553779, encodeId=3d0e1553e790d, content=<a href='/topic/show?id=5332126e5b5' target=_blank style='color:#2F92EE;'>#NETs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12675, encryptionId=5332126e5b5, topicName=NETs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16414422875, createdName=wincls, createdTime=Mon Jun 22 10:32:32 CST 2020, time=2020-06-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1939090, encodeId=db4a1939090a9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 04 00:32:32 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800504, encodeId=f01f1800504b7, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Jan 26 02:32:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734228, encodeId=d0d71e342281c, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Apr 08 12:32:32 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344248, encodeId=fdb7134424876, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2830, encryptionId=7649283021, topicName=ASCO 2020)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jun 22 10:32:32 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553779, encodeId=3d0e1553e790d, content=<a href='/topic/show?id=5332126e5b5' target=_blank style='color:#2F92EE;'>#NETs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12675, encryptionId=5332126e5b5, topicName=NETs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16414422875, createdName=wincls, createdTime=Mon Jun 22 10:32:32 CST 2020, time=2020-06-22, status=1, ipAttribution=)]
    2021-04-08 canlab
  4. [GetPortalCommentsPageByObjectIdResponse(id=1939090, encodeId=db4a1939090a9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 04 00:32:32 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800504, encodeId=f01f1800504b7, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Jan 26 02:32:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734228, encodeId=d0d71e342281c, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Apr 08 12:32:32 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344248, encodeId=fdb7134424876, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2830, encryptionId=7649283021, topicName=ASCO 2020)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jun 22 10:32:32 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553779, encodeId=3d0e1553e790d, content=<a href='/topic/show?id=5332126e5b5' target=_blank style='color:#2F92EE;'>#NETs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12675, encryptionId=5332126e5b5, topicName=NETs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16414422875, createdName=wincls, createdTime=Mon Jun 22 10:32:32 CST 2020, time=2020-06-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1939090, encodeId=db4a1939090a9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 04 00:32:32 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800504, encodeId=f01f1800504b7, content=<a href='/topic/show?id=cbf9e254051' target=_blank style='color:#2F92EE;'>#相关研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72540, encryptionId=cbf9e254051, topicName=相关研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Jan 26 02:32:32 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734228, encodeId=d0d71e342281c, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Thu Apr 08 12:32:32 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344248, encodeId=fdb7134424876, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2830, encryptionId=7649283021, topicName=ASCO 2020)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Jun 22 10:32:32 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553779, encodeId=3d0e1553e790d, content=<a href='/topic/show?id=5332126e5b5' target=_blank style='color:#2F92EE;'>#NETs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12675, encryptionId=5332126e5b5, topicName=NETs)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a16414422875, createdName=wincls, createdTime=Mon Jun 22 10:32:32 CST 2020, time=2020-06-22, status=1, ipAttribution=)]
    2020-06-22 wincls